Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

NCT07322783 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

EGFR Positive Non-small Cell Lung Cancer
MET Amplification

Interventions

DRUG: • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets

Sponsor

Qingdao Central Hospital